| Autor: |
Jungwirth U; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Department of Pharmacy and Pharmacology, Centre for Therapeutic Innovation, University of Bath, Bath, UK., van Weverwijk A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Evans RJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Jenkins L; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Vicente D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Alexander J; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Gao Q; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Strategic Initiatives, Data Science, The Institute of Cancer Research, Sutton, UK., Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Iravani M; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Isacke CM; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. clare.isacke@icr.ac.uk. |
| Abstrakt: |
Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is hampered by the lack of specific markers defining these populations. Here we show that genetic deletion of the Endo180 (MRC2) receptor, predominantly expressed by a population of matrix-remodelling CAFs, profoundly limits tumour growth and metastasis; effects that can be recapitulated in 3D co-culture assays. This impairment results from a CAF-intrinsic contractility defect and reduced CAF viability, which coupled with the lack of phenotype in the normal mouse, demonstrates that upregulated Endo180 expression by a specific, potentially targetable CAF subset is required to generate a supportive tumour microenvironment. Further, characterisation of a tumour subline selected via serial in vivo passage for its ability to overcome these stromal defects provides important insight into, how tumour cells adapt to a non-activated stroma in the early stages of metastatic colonisation. |
Full text from SpringerLink